|
gptkbp:instanceOf
|
gptkb:antibiotic
|
|
gptkbp:approvalYear
|
2003
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J01XX09
|
|
gptkbp:brand
|
gptkb:Cubicin
|
|
gptkbp:CASNumber
|
103060-53-3
|
|
gptkbp:chemicalFormula
|
C72H101N17O26
|
|
gptkbp:contraindication
|
known hypersensitivity to daptomycin
|
|
gptkbp:developedBy
|
gptkb:Cubist_Pharmaceuticals
|
|
gptkbp:drugClass
|
lipopeptide antibiotic
|
|
gptkbp:eliminationHalfLife
|
8 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:genericName
|
gptkb:daptomycin
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cubicin
|
|
gptkbp:indication
|
methicillin-resistant Staphylococcus aureus (MRSA) infections
vancomycin-resistant Enterococcus (VRE) infections
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
disrupts bacterial cell membrane
|
|
gptkbp:metabolism
|
minimal
|
|
gptkbp:molecularWeight
|
1620.67 g/mol
|
|
gptkbp:notEffectiveAgainst
|
gptkb:pneumonia
|
|
gptkbp:pregnancyCategory
|
B (US)
B1 (Australia)
|
|
gptkbp:proteinBinding
|
92%
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
muscular dystrophy
eosinophilic pneumonia
gastrointestinal disturbances
|
|
gptkbp:usedFor
|
treatment of complicated skin and skin structure infections
treatment of Staphylococcus aureus bloodstream infections
|
|
gptkbp:bfsParent
|
gptkb:Merck_&_Co.
|
|
gptkbp:bfsLayer
|
4
|